Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.

European journal of neurology - 1 Feb 2009

van Oostrom J C H, Dekker M, Willemsen A T M, de Jong B M, Roos R A C, Leenders K L

Abstract excerpt

BACKGROUND: Carriers of the Huntington disease (HD) mutation develop a progressive neurodegenerative disorder after a pre-clinical phase. We examined the value of (11)C-raclopride PET (RAC) as a biomarker for pre-clinical HD pathophysiology. METHODS: In a prospective cohort study with clinical and neuropsychological assessment we collected complete RAC data in 18 pre-clinical mutation carriers (HD-PMC) and 11...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Huntingtin Protein
Share to Huntington Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Corpus Striatum

Share to Image Interpretation, Computer-Assisted

Share to Neuropsychological Tests

Share to Positron-Emission Tomography

Share to Radiopharmaceuticals

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 19138335
DOI: 10.1111/j.1468-1331.2008.02390.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.PMID 19138335Read ↗

Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.Semantic proximity Read ↗

Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's diseaseSemantic proximity Read ↗

Molecular Imaging Markers to Track Huntington’s Disease PathologySemantic proximity Read ↗

Hypothalamic involvement in Huntington's disease: an in vivo PET studySemantic proximity Read ↗

Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.Semantic proximity Read ↗

Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography.Semantic proximity Read ↗

Molecular Imaging of Huntington's Disease.Semantic proximity Read ↗

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.Semantic proximity Read ↗

[11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat lengthSemantic proximity Read ↗

Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's diseaseSemantic proximity Read ↗

Understanding the role of dopamine in pathology and cognition in Huntington's diseaseSemantic proximity Read ↗

Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.